Experience

Davis Polk advised Charles River Laboratories International, Inc. in connection with its Rule 144A/Regulation S offering of $500 million aggregate principal amount of 5.500% senior notes…

Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by Omnicell, Inc. of its shares of common stock for up to an aggregate amount of $125…

Davis Polk advised the sole book-running manager on an SEC-registered offering by Celgene Corporation of $500 million aggregate principal amount of 2.250% senior notes due 2021. …

Davis Polk advised the administrative agent in connection with a $3.1 billion best-efforts financing comprised of a $1 billion senior secured term loan A facility, a $1.6 billion senior…

Davis Polk advised the representatives of the several underwriters in connection with the $103.5 million initial public offering of common stock of Kala Pharmaceuticals, Inc. The…

Davis Polk advised the representatives of the underwriters, in connection with the offering of €1 billion aggregate principal amount of notes issued by Merck & Co., Inc. The notes were…

Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $719 million initial public offering by Patheon N.V. (“Patheon”). The IPO comprised…

Davis Polk advised McKesson Corporation on its creation of a new health care information technology company, which will combine substantially all of Change Healthcare Holdings, Inc.’s…

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Universal American Corp. of an aggregate principal amount of $115 million of 4.00% convertible senior…

Davis Polk advised the representatives of the underwriters, in connection with an SEC-registered offering by AbbVie Inc. (“AbbVie”) of $7.8 billion aggregate principal amount of senior…